X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-08-24 | XENE | Svoronos Dawn | Dir | S - Sale | $38.70 | -25,000 | 25,000 | -50% | -$967,500 | ||||||
| DM | 2023-05-30 | XENE | Pimstone Simon N. | Dir | S - Sale+OE | $38.90 | -131,245 | 6,000 | -96% | -$5,104,970 | |||||
| D | 2023-05-24 | XENE | Mortimer Ian | Pres, CEO | S - Sale+OE | $41.41 | -31,655 | 45,602 | -41% | -$1,310,931 | |||||
2023-03-24 | XENE | Kenney Christopher John | Chief Medical Officer | S - Sale | $35.01 | -700 | 0 | -100% | -$24,507 | ||||||
| D | 2023-03-07 | XENE | Pimstone Simon N. | Dir | S - Sale+OE | $36.98 | -19,232 | 55,006 | -26% | -$711,199 | |||||
| DM | 2022-11-23 | XENE | Patou Gary | Dir | S - Sale+OE | $34.55 | -3,994 | 36,073 | -10% | -$138,000 | |||||
| D | 2022-09-02 | XENE | Aulin Sherry | CFO | S - Sale+OE | $39.57 | -15,355 | 0 | -100% | -$607,597 | |||||
| DM | 2022-08-31 | XENE | Robin Sherrington | EVP, Strategy, Innovation | S - Sale+OE | $38.31 | -65,231 | 16,796 | -80% | -$2,499,023 | |||||
| D | 2022-08-12 | XENE | Empfield James R. | EVP, Drug Discovery | S - Sale+OE | $38.31 | -57,743 | 10,000 | -85% | -$2,211,978 | |||||
| M | 2022-08-12 | XENE | Pimstone Simon N. | Dir | S - Sale | $38.25 | -177,135 | 6,000 | -97% | -$6,775,149 | |||||
| A | 2022-03-08 | XENE | Pimstone Simon N. | Dir | S - Sale | $30.80 | -2,500 | 193,135 | -1% | -$77,000 | |||||
| DM | 2022-03-04 | XENE | Pimstone Simon N. | Dir | S - Sale+OE | $29.28 | -54,962 | 183,135 | -23% | -$1,609,321 | |||||
| D | 2022-03-04 | XENE | Robin Sherrington | EVP, Strategy, Innovation | S - Sale+OE | $30.50 | -21,710 | 17,232 | -56% | -$662,208 | |||||
| DM | 2022-03-04 | XENE | Empfield James R. | EVP, Drug Discovery | S - Sale+OE | $30.63 | -51,168 | 10,000 | -84% | -$1,567,394 | |||||
2022-01-21 | XENE | Kenney Christopher John | Chief Medical Officer | P - Purchase | $28.81 | +700 | 700 | New | +$20,167 | ||||||
2021-12-06 | XENE | Von Seggern Christopher | Chief Commercial Officer | P - Purchase | $24.40 | +4,000 | 4,000 | New | +$97,600 | ||||||
2021-11-15 | XENE | Pimstone Simon N. | Dir | S - Sale | $31.33 | -17,557 | 210,186 | -8% | -$550,061 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |